PFU
MRNA icon

Parus Finance (UK)’s Moderna MRNA Stock Holding History

Parus Finance (UK)’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-26,328
Closed -$3.13M – 36
2024
Q2 		$3.13M Buy
26,328
+444
+2% +$56.2K 0.9% 21
2024
Q1 		$2.76M Sell
25,884
-1,194
-4% -$120K 1.04% 20
2023
Q4 		$2.69M Sell
27,078
-316
-1% -$26.6K 1.4% 17
2023
Q3 		$2.83M Sell
27,394
-3,404
-11% -$380K 1.76% 17
2023
Q2 		$3.74M Sell
30,798
-1,381
-4% -$184K 1.55% 15
2023
Q1 		$4.94M Buy
32,179
+572
+2% +$94.4K 2.96% 11
2022
Q4 		$5.68M Buy
31,607
+4,740
+18% +$775K 3.86% 11
2022
Q3 		$3.18M Sell
26,867
-12,510
-32% -$1.9M 2.76% 12
2022
Q2 		$5.63M Buy
39,377
+30,010
+320% +$4.29M 3.35% 15
2022
Q1 		$1.61M Sell
9,367
-3,296
-26% -$555K 0.58% 26
2021
Q4 		$3.22M Sell
12,663
-15,244
-55% -$4.46M 1.03% 23
2021
Q3 		$10.7M Sell
27,907
-49,163
-64% -$18.1M 3.1% 11
2021
Q2 		$18.1M Buy
77,070
+7,201
+10% +$1.29M 4.39% 7
2021
Q1 		$9.15M Buy
69,869
+19,859
+40% +$2.88M 2.51% 15
2020
Q4 		$5.22M Buy
+50,010
New +$5.06M 1.53% 22

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Parus Finance (UK)'s MRNA Position: Q3 2024 in Review

Parus Finance (UK) sold out of Moderna (MRNA) in Q3 2024, closing a stake of 26,328 shares — an estimated $3.13M sold.

Parus Finance (UK) first reported a position in MRNA in Q4 2020 and held it in 15 quarters. The position peaked at $18.1M in Q2 2021. 789 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Parus Finance (UK) reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Parus Finance (UK) sold 26,328 Moderna shares in Q3 2024, an estimated $3.13M.
  • Parus Finance (UK) first reported a position in Moderna in Q4 2020 and held it in 15 quarters.
  • Parus Finance (UK)'s Moderna position peaked at $18.1M in Q2 2021.
  • 789 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Parus Finance (UK)'s 13F filing for Q3 2024, filed 14 Nov 2024.